Bayer has announced successful results from a Phase III clinical trial evaluating its investigational PET tracer, iodine 124 evuzamitide, designed for diagnosing cardiac amyloidosis. The trial, named the REVEAL study, demonstrated significant sensitivity and specificity in identifying this condition through visual scan interpretation with PET/CT imaging. These results are anticipated to be discussed with the U.S. Food and Drug Administration (FDA) and other health authorities for potential regulatory submissions.
Cardiac amyloidosis is a serious disease characterized by the accumulation of amyloid proteins in heart tissue, leading to impaired cardiac function. The condition is often underdiagnosed, with symptom onset to diagnosis averaging 2 to 4 years. Accurate diagnostic tools are crucial, as early detection can prevent further organ damage. Currently, no single non-invasive test reliably detects and diagnoses cardiac amyloidosis.
Bayer's iodine 124 evuzamitide has previously been granted Breakthrough Therapy Designation and Orphan Drug status by the FDA and the European Medicines Agency for its role in diagnosing amyloidoses, specifically light-chain (AL) and transthyretin (ATTR) amyloidoses. These designations reflect its potential to meet unmet medical needs in diagnosing rare conditions.